Illinois Prescription Monitoring Program

Update - April 2023

Subscribe to follow us @ILPMP on YouTube

View as Webpage

Rx and Illicit Drug Summit

Article Heading

ILPMP Clinical Director, Sarah Pointer, Pharm D had the opportunity to attend Rx and Illicit Drug Summit in Atlanta, Georgia - April 10-13. Rx Summit is the largest, most influential event addressing this crisis, where strategies are shared and put into action. This global community is made up of multidisciplinary stakeholders "from federal to family". This conference is held to learn the latest strategies for prevention, treatment, and recovery.

Text Link

Frequently Asked Questions

Q: Who must register with the ILPMP?

A: All prescribers with a State of Illinois issued controlled substance license must register with the ILPMP regardless of practice type. It is mandatory to search the ILPMP upon prescribing Schedule II-V controlled substances.

Q: How do I reset my password?

A: To reset password, click Forgot Password. Follow prompts to enter e-mail address and state license number.

Q: How much data does ILPMP contain?

A: 12 months

Q: Can I share my password?

A: No. Please add a delegate account.

ILPMP Advisory Committee Meeting

The ILPMP Advisory Committee Meeting was held on March 14 via Webex with all members in attendance. Topics of interest included: Introduction of new pharmacist member, Tran Tran, Pharm D., BCPS, legislation updates, PMPnow overview, Peer Review updates, and a 2022 Data Trend recap. Advisory Committee information, including minutes, can be found on ilpmp.org in the About Us section.

Xylazine Update

White House Designates Xylazine as an Emerging Drug Threat.

In our March ILPMP newsletter, we shared that Xylazine, an emerging drug overdose threat, has been involved in an increasing number of overdoses and other health issues.

We are sharing additional important information about the emerging drug overdose threat. The U.S. Drug Enforcement Administration is warning the American public of a sharp increase in the trafficking of fentanyl mixed with Xylazine.

Xylazine is a powerful sedative that the U.S. Food and Drug Administration has approved for veterinary use. When mixed with fentanyl, Xylazine increases the risk of a fatal overdose.

White House Designates Xylazine as an Emerging Drug Threat. This designation requires the Biden Administration to create strategies to enhance law enforcement efforts, health intervention and data collection to combat xylazine. This is the first time that the White House’ Office of National Drug Control Policy (ONDCP) has ever identified a substance for that designation – an indication of the grave dangers it considers to be posed by xylazine.

Illinois Department of Human Services - Division of Substance Use Prevention and Recovery Newsletter, April 2023

Upcoming Echo Trainings For Opioid Use Disorder Prescribers and Teams!

The purpose of this fellowship program is to train primary care providers (physicians, nurse practitioners, and physician assistants) in the assessment and treatment of opioid use disorders (OUD). The goal of the nine-month program is to increase access to opioid use disorder treatment services in areas of the state that currently have limited or no access to medications for addiction treatment. Therefore, providers from these areas will receive priority for admission.

The training will provide clinical guidance, technical support around the clinical workflows, policies and protocols to ensure compliance with clinical standards, and training in evidence-based practice.

More Information

Educational Resources

NEW Webinar: Continuing Medical Education

Benefits of a Designee

CME to go LIVE May 8, 2023

Webinar

Describe the ILPMP program and registration process

Explain how a prescriber can assign a designee

Identify the capabilities and responsibilities of a prescriber and designee within the ILPMP

Discuss the importance and benefits of assigning designee(s)

1.0 contact hour CME

Staffing Update

Welcome to the team!

ILPMP would like to welcome two new interns to the team. They will be assisting with registrations, users, and general reporting. Please join us in welcoming each member into their new roles on the IT team!

Sameer Ahmed Pasha Mohammed Abdul

Glory Stephen-Kings

ILPMP.ORG & PMPnow Monthly Data

Contact Information

If you have questions about the information that appears in this update, or suggestions for future content, please email dhs.pmp@illinois.gov. Visit www.ilpmp.org for more information.

The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data on Schedule II-V controlled substances, selected drugs of interest, and other health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.